Hepatitis C

Stay updated on the biggest headlines with MDNN from November 10, 2017.

Just 55% of the 2.7 million people believed to be living with HCV in the US are aware.

Patients with HCV infection achieved the same rates of sustained virologic response regardless of whether they were treated by a specialist or non-specialist provider.

The research team gauged nearly 3,500 HCV patients who had attained SVR on sofosbuvir.

The VA declares it is "poised to share" its methods and success in reaching and treating patients with HCV.

Aspirin is known for its strong anti-inflammatory properties, and has been explored for its chemopreventive effects in cancers related to chronic inflammation.

A new study of HCV infection rates among pregnant women in Wisconsin comes at a time of increased concern about opioid abuse.

As many as 8% of pregnant women worldwide are infected with HCV.

“Developing novel ideas to further improve HCV screening and linkage to care are needed."

Young injection drug users with HCV benefit from a cost-effective method of viral testing.

Ribavirin steady-state plasma level rather than weight-based dose was found to be an independent predictor of sustained virologic response in patients with HCV.

The effectiveness of these DAAs on such patients has not been evaluated, even though the prevalence of the liver-attacking virus among heart recipients ranges from 7% to 18%.

Direct acting antiviral regimens are approved to treat HCV genotype 1 over 12 to 24 weeks, but recent trial results suggest 8 weeks could be sufficient.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about challenges of Hepatitis C treatment.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the current state and future of Hepatitis C.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the challenges treating co-infected HIV and HCV patients.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the hottest topic in infectious disease.

Physicians looking to provide effective treatment to co-infected patients mustn't overlook uncontrolled viremia or substance abuse, according to a new study.

The CDC and local agencies have partnered to combat the outbreak, but it’s not under control yet.

National reports show less treated patients and less spending in a field that major developers are now leaving.

Individuals engaged in riskier behaviors and relationships appear to be more inclined to continue taking treatment.

Treating opioid use disorder can reduce mortality and curb spreading infections in people who use drugs.

Findings from an assessment of HCV treatment in over 62,000 patients refutes the suggestion that treatment with DAAs promotes recurrence of HCC.

The pharmaceutical company follows Johnson & Johnson's pursuit of fields outside of hepatitis C.

According to the FDA, Ocaliva has been identified in 19 cases of death and 11 cases of serious liver damage, and has been excessively dosed in some adult patients with moderate to severe decreases in liver function.

HCV-positive women of childbearing age undergo premature ovarian deterioration, researchers wrote.

All of the 13 patients with genotype 2 achieved SVR after 12 weeks of treatment, and in those with genotype 3, the SVR rate was 97%.

While 52% of patients were eligible for treatment, only 60% of them received it. For the 47% of individuals who weren’t eligible, the most common reason was their inability to provide pre-treatment workups including serologic testing and assessment for liver fibrosis and inflammation.

Hepatitis C drug treatment resistance can be met and defeated by longer treatment or additional agent.

Worldwide HCV prevalence in 2017 dropped 2% from 2015 levels to 69.6 million viremic infections, thanks to increased treatment and prevention.